logo

For the Inventor, By the Inventor

Lyon, France

Poxel


USPTO Granted Patents = 13

% Expired Patents = 23.1



Forward Citations = 28

Loading Chart...
Loading Chart...

32 inventors (with patents filed for the assignee):

goldMedal Daniel Cravo (9 out of 26 patents)

silverMedal Sophie Hallakou-Bozec (7 out of 14 patents)

bronzeMedal Sébastien Bolze (6 out of 11 patents)

4.  Pascale Fouqueray (3 out of 3 patents)

5.  Jean-Denis Durand (2 out of 6 patents)

6.  Amaury Patin (2 out of 10 patents)

7.  Franck F Lepifre (2 out of 12 patents)

8.  Patrice Andre (2 out of 37 patents)

9.  Pauline Radreau (2 out of 2 patents)

10.  Vincent Lotteau (2 out of 10 patents)

11.  Marine Gilardone (2 out of 2 patents)

12.  Christine G Charon (2 out of 28 patents)

13.  Laurent Faveriel (2 out of 2 patents)

14.  Didier Mesangeau (2 out of 13 patents)

15.  Matthias Helmreich (2 out of 3 patents)


13 patents:

1. 12319700 - Monohydrate potassium salt of a thienopyridone derivative and its preparation process (2025-06-03),
2. 12310949 - Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (ADPKD) (2025-05-27),
3. 11850238 - Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy (2023-12-26),
4. 10071108 - Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection (2018-09-11),
5. 9895380 - Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection (2018-02-20),
6. 9365584 - Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof (2016-06-14),
7. 9284329 - Thienopyridone derivatives useful as activators of AMPK (2016-03-15),
8. 9271984 - Treatment of type 1 diabetes (2016-03-01),
9. 9035048 - Tetrahydrotriazine compounds for treating diseases associated with AMPK activity (2015-05-19),
10. 8937066 - Amino derivatives of dihydro-1,3,5-triazine used in the treatment of ischemia and/or reperfusion related diseases (2015-01-20),
11. 8846911 - Process of isolating enantiomer components from enantiomer mixtures by particle-size-controlled crystallization (2014-09-30),
12. 8742103 - Separation of triazine derivatives enantiomers using tartaric acid (2014-06-03),
13. 8742102 - Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization (2014-06-03),
Poxel is a biopharmaceutical company based in Lyon, France, specializing in the development of innovative therapies for metabolic diseases, particularly diabetes and obesity. The company focuses on advancing its proprietary drug candidates through rigorous research and development, leveraging expertise in pharmacology and metabolic science. Poxel aims to address unmet medical needs by creating effective treatments that improve patient outcomes and enhance quality of life in the field of metabolic health.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

13 Patents

#30 in Lyon

#1,398 in France

#44,950 in the World

Lyon, FR
Lyon, France

Poxel

Forward Citations = 28

32 inventors:

goldMedal Daniel Cravo (9 out of 26 patents)

silverMedal Sophie Hallakou-Bozec (7 out of 14 patents)

bronzeMedal Sébastien Bolze (6 out of 11 patents)

4.  Pascale Fouqueray (3 out of 3 patents)

5.  Jean-Denis Durand (2 out of 6 patents)

Please report any incorrect information to [email protected]
Loading…